High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial.

Department of Neurosciences, University of California, San Diego, 9500 Gilman Dr, M/C 0949, La Jolla, CA 92093, USA.
JAMA The Journal of the American Medical Association (Impact Factor: 29.98). 10/2008; 300(15):1774-83. DOI: 10.1001/jama.300.15.1774
Source: PubMed

ABSTRACT Blood levels of homocysteine may be increased in Alzheimer disease (AD) and hyperhomocysteinemia may contribute to disease pathophysiology by vascular and direct neurotoxic mechanisms. Even in the absence of vitamin deficiency, homocysteine levels can be reduced by administration of high-dose supplements of folic acid and vitamins B(6) and B(12). Prior studies of B vitamins to reduce homocysteine in AD have not had sufficient size or duration to assess their effect on cognitive decline.
To determine the efficacy and safety of B vitamin supplementation in the treatment of AD.
A multicenter, randomized, double-blind controlled clinical trial of high-dose folate, vitamin B(6), and vitamin B(12) supplementation in 409 (of 601 screened) individuals with mild to moderate AD (Mini-Mental State Examination scores between 14 and 26, inclusive) and normal folic acid, vitamin B(12), and homocysteine levels. The study was conducted between February 20, 2003, and December 15, 2006, at clinical research sites of the Alzheimer Disease Cooperative Study located throughout the United States.
Participants were randomly assigned to 2 groups of unequal size to increase enrollment (60% treated with high-dose supplements [5 mg/d of folate, 25 mg/d of vitamin B(6), 1 mg/d of vitamin B(12)] and 40% treated with identical placebo); duration of treatment was 18 months.
Change in the cognitive subscale of the Alzheimer Disease Assessment Scale (ADAS-cog).
A total of 340 participants (202 in active treatment group and 138 in placebo group) completed the trial while taking study medication. Although the vitamin supplement regimen was effective in reducing homocysteine levels (mean [SD], -2.42 [3.35] in active treatment group vs -0.86 [2.59] in placebo group; P < .001), it had no beneficial effect on the primary cognitive measure, rate of change in ADAS-cog score during 18 months (0.372 points per month for placebo group vs 0.401 points per month for active treatment group, P = .52; 95% confidence interval of rate difference, -0.06 to 0.12; based on the intention-to-treat generalized estimating equations model), or on any secondary measures. A higher quantity of adverse events involving depression was observed in the group treated with vitamin supplements.
This regimen of high-dose B vitamin supplements does not slow cognitive decline in individuals with mild to moderate AD. Identifier: NCT00056225.

1 Bookmark
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: As tau aggregation pathology correlates with clinical dementia in Alzheimer's disease (AD), a tau aggregation inhibitor (TAI) could have therapeutic utility. Methylthioninium (MT) acts as a selective TAI in vitro and reduces tau pathology in transgenic mouse models. Objective: To determine the minimum safe and effective dose of MT required to prevent disease progression on clinical and functional molecular imaging outcomes. Methods: An exploratory double-blind, randomized, placebo-controlled, dose-finding trial of MT (69, 138, and 228 mg/day) was conducted in 321 mild/moderate AD subjects. The primary outcome was change on the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) at 24 weeks relative to baseline severity. Effect of treatment on regional cerebral blood flow decline was determined in a sub-study in 135 subjects. After 24 weeks, subjects were re-consented to enter sequential 6- and 12-month blinded extension phases. Registered with (NCT00515333). Results: At 24 weeks, there were significant treatment benefits in two independent populations at the 138 mg/day dose: in moderate subjects on the ADAS-cog scale (treatment effect: -5.42 units, corrected p = 0.047) and two other clinical scales; in mild subjects on the more sensitive regional cerebral blood flow measure (treatment effect: 1.97%, corrected p < 0.001). With continued treatment for 50 weeks, benefit was seen on the ADAS-cog scale in both mild and moderate subjects. The delivery of the highest dose was impaired due to dose-dependent dissolution and absorption limitations. Conclusion: The minimum safe and effective daily MT dose is 138 mg and suggests that further study of MT is warranted in AD.
    Journal of Alzheimer's disease: JAD 12/2014; 44(2). DOI:10.3233/JAD-142874 · 3.61 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: A moderate elevation of plasma total homocysteine (tHcy) is considered a potential risk factor for Alzheimer's disease (AD). Methods: We have investigated the main determinants (age, renal impairment, cobalamin/folate status and the presence of vascular disease) of plasma tHcy in 326 patients with AD, and also in 281 patients with mild cognitive impairment (MCI), since about half of these patients develop AD during the first 5 years. Results: Elevated plasma tHcy in patients with AD could mainly be attributed to cobalamin/folate deficiency or renal impairment. Younger patients (below 75 years) with AD and patients with MCI without cobalamin/folate deficiency or renal impairment showed normal levels of plasma tHcy. Conclusion: Our findings suggest that plasma tHcy is not primarily involved in the pathogenesis of AD but rather a reflection of changes of the main determinants of plasma tHcy in AD patients. Copyright (C) 2012 S. Karger AG, Basel
    Dementia and Geriatric Cognitive Disorders 01/2012; 34(2):121-127. DOI:10.1159/000342612 · 2.79 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: A folic acid and other B-group vitamins have a direct impact on proper functioning of the nervous system and cognitive functions. Aim of the study: The aim of the study was to assess the consumption of the folic acid and B-group vitamins and to analyze the relation between these vitamins in a diet and results of the cognitive function of women after menopause. Material and methods: The examined women came from south-east Poland and were at least 2 years after their last menstruation. The women's age was 50-65 and they had an overall good state of health, at least an elementary education and FSH > 30 mlU/ml. The qualification stage included a MoCA test in order to exclude women with dementia. The cognitive function assessment was conducted with the CNS - Vital Signs diagnostic equipment (Polish version). The content of vitamins was determined through a 7-day observation of a diet with the DIETETYK computer application developed by the National Food and Nutrition Institute. The results were analyzed statistically. Results: The results show that around half of the examined women had lower than average results in most of cognitive function tests. The most serious disorders concerned the processing speed and the least serious verbal and eye memory. The diet of the examined women lacked B vitamins (not B-12 vitamin) and folic acid. The best results in the reaction time were recorded among women who consumed B-2 according to the norm.
    Menopausal Review 12/2013; 6(6):464-471. DOI:10.5114/pm.2013.39810 · 0.38 Impact Factor

Full-text (3 Sources)

Available from
Mar 4, 2015